Senti Biosciences Holdings (SNTI) Total Non-Current Liabilities (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Total Non-Current Liabilities of $37.5 million for Q4 2025, down 10.71% year-over-year from $42.0 million in Q4 2024, and up 1.46% quarter-over-quarter from $37.0 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $37.5 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 10.71% year-over-year to $37.5 million; the TTM figure through Dec 2025 stood at $37.5 million (down 10.71% YoY), while the FY2025 annual figure was $37.5 million, down 10.71% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $37.5 million, up from $37.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $53.3 million in Q4 2022, with the low at $36.3 million in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $44.1 million (2024), against an average of $43.4 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 46.73% in 2022, then fell 16.74% in 2025.
- Senti Biosciences Holdings' Total Non-Current Liabilities stood at $36.3 million in 2021, then surged by 46.73% to $53.3 million in 2022, then dropped by 13.25% to $46.2 million in 2023, then slipped by 9.09% to $42.0 million in 2024, then decreased by 10.71% to $37.5 million in 2025.
- Business Quant data shows SNTI's Total Non-Current Liabilities at $37.5 million in Q4 2025, $37.0 million in Q3 2025, and $36.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | 28.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 37.54 Mn |
| Sep 30, 2025 | 37.00 Mn |
| Jun 30, 2025 | 36.32 Mn |
| Mar 31, 2025 | 38.36 Mn |
| Dec 31, 2024 | 42.04 Mn |
| Sep 30, 2024 | 41.63 Mn |
| Jun 30, 2024 | 40.38 Mn |
| Mar 31, 2024 | 46.07 Mn |
| Dec 31, 2023 | 46.24 Mn |
| Sep 30, 2023 | 48.81 Mn |
| Jun 30, 2023 | 46.19 Mn |
| Mar 31, 2023 | 48.92 Mn |
| Dec 31, 2022 | 53.30 Mn |
| Sep 30, 2022 | 48.19 Mn |
| Jun 30, 2022 | 47.29 Mn |
| Dec 31, 2021 | 36.33 Mn |